Thursday, Jan 18, 1990

Biogen and Genentech Enter Into Cross-License Agreement for Gamma Interferon in The United States

Cambridge, Mass. -- January 18, 1990 --

Biogen, Inc. (NASDAQ/BGEN) and Genentech, Inc. (NYSE/GNE) have entered into a cross-license agreement for human recombinant gamma interferon in the United States. Under the agreement, each company will be able to sell its gamma interferon product for specific therapeutic and diagnostic applications. At the same time, Biogen granted Genentech a non-exclusive world-wide license for process patents relating to the secretion of proteins.

Biogen has conducted clinical trials in the United States with Immuneron™, gamma interferon for treatment of two conditions, rheumatoid arthritis and venereal warts. Later this year, Biogen expects to complete a Phase II trial in the United States with Immuneron as treatment for venereal warts. Biogen's gamma interferon product is being developed in the United States through the Biogen Medical Products Limited Partnership.

Genentech has filed a Product License Aplication with the Food and Drug Administration to seek approval to market Actimmune™, gamma interferon to treat patients with chronic granulomatous disease (CGD). CGD is a rare, inherited disorder which is characterized by an impaired immune system. In addition, Genentech is conducting Phase III clinical trials to evaluate Actimmune's usefulness in treating infections in patients who have endured severe trauma, and as an adjuvant therapy in the treatment of patients with malignant melanoma and small-cell cancer of the lung.

Biogen is a leading biotechnology company principally engaged in developing genetically engineered pharmaceuticals. As a result of its early research, Biogen now derives revenues from five products being sold by its licensees in various countries. Biogen currently directs its research and development into areas where the company has particular strength -- AIDS, inflammation and selected cancers.

Genentech, Inc. is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology. Genentech markets two products that produce over $100 million in sales each: Protropin®, human growth hormone, for the treatment of of children with growth hormone inadequacy, and Activase®, t-PA, a clot dissolving drug for the treatment of heart attacks.

# # #